Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.
2.

Coronary and cardiovascular risk estimation in uncomplicated mild hypertension. A comparison of risk assessment methods.

Yikona JI, Wallis EJ, Ramsay LE, Jackson PR.

J Hypertens. 2002 Nov;20(11):2173-82.

PMID:
12409955
3.

Cardiovascular and coronary risk estimation in hypertension management.

Wallis EJ, Ramsay LE, Jackson PR.

Heart. 2002 Sep;88(3):306-12. Review. No abstract available.

4.

Statins for primary prevention: at what coronary risk is safety assured?

Jackson PR, Wallis EJ, Haq IU, Ramsay LE.

Br J Clin Pharmacol. 2001 Oct;52(4):439-46.

5.

Prevention of stroke and transient ischaemic attack.

Jackson PR, Wallis EJ, Ramsay LE.

Lancet. 2001 Sep 1;358(9283):762. No abstract available.

PMID:
11556348
6.

Population implications of lipid lowering for prevention of coronary heart disease: data from the 1995 Scottish health survey.

Haq IU, Ramsay LE, Wallis EJ, Isles CG, Ritchie LD, Jackson PR.

Heart. 2001 Sep;86(3):289-95.

7.

Is coronary risk an accurate surrogate for cardiovascular risk for treatment decisions in mild hypertension? A population validation.

Wallis EJ, Ramsay LE, Haq IU, Ghahramani P, Jackson PR.

J Hypertens. 2001 Apr;19(4):691-6.

PMID:
11330871
8.

Aspirin for primary prevention. Treatment policy should be based on all trial evidence, not subgroup analysis.

Ramsay LE, Sanmuganathan PS, Wallis EJ, Jackson PR.

BMJ. 2000 Dec 9;321(7274):1472. No abstract available.

9.
10.

Optimal age for starting lipid lowering treatment. Adjusted date do not justify a lower optimal age.

Jackson PR, Wallis EJ, Ramsay LE.

BMJ. 2000 Sep 9;321(7261):637-8. No abstract available.

PMID:
11023329
11.

Comparison of methods of estimating coronary risk. Authors did not use latest version of Sheffield table.

Wallis EJ, Ramsay LE, Yikona JI, Jackson PR.

BMJ. 2000 Jul 15;321(7254):175-6. No abstract available.

12.

Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population.

Wallis EJ, Ramsay LE, Ul Haq I, Ghahramani P, Jackson PR, Rowland-Yeo K, Yeo WW.

BMJ. 2000 Mar 11;320(7236):671-6. Erratum in: BMJ 2000 Apr 15;320(7241):1034.

13.

Prediction of coronary risk for primary prevention of coronary heart disease: a comparison of methods.

Haq IU, Ramsay LE, Jackson PR, Wallis EJ.

QJM. 1999 Jul;92(7):379-85.

PMID:
10627887
14.

Implication of recent trials with b-hydroxy-b-methylglutaryl coenzyme A reductase inhibitors for hypertension management.

Haq IU, Wallis EJ, Jackson PR, Yeo WW, Ramsay LE.

J Hypertens. 1999 Nov;17(11):1641-6.

PMID:
10608479
15.

Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients.

Yeo KR, Yeo WW, Wallis EJ, Ramsay LE.

Br J Clin Pharmacol. 1999 Oct;48(4):610-5.

17.

Cholesterol screening and management guidelines. Policy based on Sheffield table fully satisfies authors' criteria.

Ramsay LE, Wallis EJ, Haq IU, Jackson PR, Yeo WW.

BMJ. 1999 Apr 24;318(7191):1140-1. No abstract available.

PMID:
10366266
18.

Coronary risk assessment methods and cholesterol lowering.

Ramsay LE, Wallis EJ, Haq IU, Jackson PR.

Lancet. 1999 Mar 27;353(9158):1095; author reply 1096-7. No abstract available.

PMID:
10199369
19.

Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Haq IU, Wallis EJ, Yeo WW, Jackson PR, Ramsay LE.

JAMA. 1999 Feb 3;281(5):414; author reply 417-9. No abstract available.

PMID:
9952191
20.

Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension.

Wallis EJ, Ramsay LE, Hettiarachchi J.

Clin Pharmacol Ther. 1998 Oct;64(4):439-49.

PMID:
9797801
21.

Cholestanol and survival with simvastatin. More data are needed.

Wallis EJ, Williamson R, Ramsay LE, Yeo WW, Jackson PR.

BMJ. 1998 Oct 31;317(7167):1252-3. No abstract available.

22.

Statins for prevention of stroke.

Wallis EJ, Ramsay LE, Yeo WW, Jackson PR.

Lancet. 1998 Sep 12;352(9131):909-10. No abstract available.

PMID:
9743018
23.

Use of statins. Sheffield table is useful.

Ramsay LE, Wallis EJ, Haq IU, Williamson R, Yeo WW, Jackson PR.

BMJ. 1998 Aug 15;317(7156):473-4. No abstract available.

24.

The rationale for differing national recommendations for the treatment of hypertension.

Ramsay LE, Wallis EJ, Yeo WW, Jackson PR.

Am J Hypertens. 1998 Jun;11(6 Pt 2):79S-88S; discussion 95S-100S. Review.

PMID:
9655567
25.

Drug therapy for coronary heart disease: the Sheffield table.

Ramsay LE, Wallis EJ, Haq IU, Yeo WW, Jackson PR.

Lancet. 1998 Feb 7;351(9100):443-4. No abstract available.

PMID:
9482325
26.

Use of statins. Evidence on effectiveness is stronger for statins than for other treatments.

Wallis EJ, Ramsay LE, Yeo WW, Jackson PR, Pickin M, Haq IU.

BMJ. 1997 Dec 13;315(7122):1618-9. No abstract available.

27.

Drug therapy for coronary heart disease: the Sheffield table.

Wallis EJ, Ramsay LE, Jackson PR, Yeo WW, Williamson R.

Lancet. 1997 Dec 20-27;350(9094):1852. No abstract available.

PMID:
9428275

Supplemental Content

Loading ...
Support Center